EUVIMEDSkopri EUVIMED
ÜbersichtsarbeitOpen access · CC BY 4.0

TDP‐43 Phosphorylation: Pathological Modification or Protective Factor Antagonizing TDP‐43 Aggregation in Neurodegenerative Diseases?

Simone Mosna, Dorothee Dormann

BioEssays · 2026-01 · 48 (1)

DOI: 10.1002/bies.70084 ↗

At a glance

Übersichtsarbeit in BioEssays, published online on 2025-11-02. Written by Simone Mosna and 1 co-authors. Institution: Institute of Molecular Physiology, Faculty of Biology, Johannes Gutenberg University, Mainz, Germany. Major MEDLINE topics: DNA-Binding Proteins, Neurodegenerative Diseases, Protein Aggregation, Pathological. Cited 11 times so far (Crossref); 140 references. The full text is freely available (open access, CC BY 4.0). Funded by: Deutsche Forschungsgemeinschaft (DFG), VERUM Foundation, Stiftung VERUM.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

TDP‐43 is a ubiquitously expressed RNA‐binding protein that aggregates in the brains of patients suffering from neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) and Alzheimer's disease. Aggregated TDP‐43 in these diseases is hyperphosphorylated in its C‐terminal intrinsically disordered region, while physiological TDP‐43 is normally unphosphorylated. Whether TDP‐43 phosphorylation is a pathological driver, or rather a protective antagonist of TDP‐43 aggregation and consequently neurodegeneration, is still debated and a matter of ongoing research. Here, we review current knowledge about TDP‐43 phosphorylation in disease and the kinases and phosphatases that regulate this post‐translational modification. We discuss how TDP‐43 phosphorylation is thought to shape TDP‐43's phase separation, aggregation and toxicity in neurodegenerative diseases. We highlight recent research that provides evidence that hyperphosphorylation antagonizes TDP‐43 phase separation and aggregation, and speculate about a potential role of condensates in TDP‐43 phosphorylation.

Subjects

MeSH terms (MEDLINE)

DNA-Binding ProteinsNeurodegenerative DiseasesProtein Aggregation, PathologicalHumansPhosphorylationProtein Processing, Post-TranslationalAmyotrophic Lateral SclerosisAnimalsFrontotemporal Dementia

Author keywords

TAR DNA binding protein of 43 kDa (TDP‐43)amyotrophic lateral sclerosis (ALS)condensatesfrontotemporal dementia (FTD)kinasesneurodegenerationphase separationphosphorylationprotein aggregation

Substances

DNA-Binding ProteinsTARDBP protein, human

Authors and institutions

  • Institute of Molecular Physiology, Faculty of Biology, Johannes Gutenberg University, Mainz, Germany.
  • International PhD Programme (IPP) of IMB Mainz, Mainz, Germany.
  • Institute of Molecular Biology (IMB), Mainz, Germany.

Funding

  • Deutsche Forschungsgemeinschaft (DFG)
  • VERUM Foundation
  • Stiftung VERUM

Cite

APA

Mosna, S., & Dormann, D. (2026). TDP‐43 Phosphorylation: Pathological Modification or Protective Factor Antagonizing TDP‐43 Aggregation in Neurodegenerative Diseases?. BioEssays, 48(1). https://doi.org/10.1002/bies.70084

Vancouver

Mosna S, Dormann D. TDP‐43 Phosphorylation: Pathological Modification or Protective Factor Antagonizing TDP‐43 Aggregation in Neurodegenerative Diseases?. BioEssays. 2026;48(1). doi:10.1002/bies.70084

BibTeX
@article{Mosna2026,
  author = {Mosna, Simone and Dormann, Dorothee},
  title = {TDP‐43 Phosphorylation: Pathological Modification or Protective Factor Antagonizing TDP‐43 Aggregation in Neurodegenerative Diseases?},
  journal = {BioEssays},
  year = {2026},
  volume = {48},
  number = {1},
  doi = {10.1002/bies.70084}
}
Start for free →